Tango Therapeutics
TNGX
89 hedge funds and large institutions have $227M invested in Tango Therapeutics in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.9% less ownership
Funds ownership: 79.18% → 77.28% (-1.9%)
3% less funds holding
Funds holding: 92 → 89 (-3)
18% less capital invested
Capital invested by funds: $276M → $227M (-$49M)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$6.39M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.09M |
| 3 |
Millennium Management
New York
|
+$401K |
| 4 |
BlackRock
New York
|
+$301K |
| 5 |
Man Group
London,
United Kingdom
|
+$300K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$16.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$555K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$351K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$312K |
| 5 |
Squarepoint
New York
|
-$189K |
TNGX Hedge Fund Activity: Q2 2023 in Review
89 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q2 2023, worth a combined $227M — down 18% from $276M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TNGX and 10 opened new positions — a net loss of 3 holders — while 31 trimmed existing stakes and 23 added.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $6.39M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $16.3M sold.
- 89 institutional investors held Tango Therapeutics (TNGX) as of Q2 2023, down from 92 in Q1 2023.
- Funds reported $227M of Tango Therapeutics stock for Q2 2023, down 18% quarter-over-quarter.
- 10 funds opened new Tango Therapeutics positions in Q2 2023 and 13 closed out, a net change of -3 holders.
- The largest Tango Therapeutics buyer in Q2 2023 was Soleus Capital Management, an estimated $6.39M added.
- The largest Tango Therapeutics seller in Q2 2023 was Cormorant Asset Management, an estimated $16.3M sold.
Based on aggregated 13F filings for Q2 2023.